



**AST 487** 

**Catalog No: tcsc0779** 

	7
J.	1
4	

## **Available Sizes**

Size: 5mg

Size: 10mg

Size: 50mg



# **Specifications**

#### CAS No:

630124-46-8

#### Formula:

 $C_{26}^{H_{30}F_{3}N_{7}O_{2}}$ 

## **Pathway:**

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

## **Target:**

VEGFR;Bcr-Abl;FLT3;c-Kit

## **Purity / Grade:**

>98%

## **Solubility:**

DMSO : ≥ 100 mg/mL (188.84 mM)

### **Alternative Names:**

NVP-AST 487

## **Observed Molecular Weight:**

529.56

# **Product Description**





AST 487 is a **RET** kinase inhibitor with  $IC_{50}$  of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **FIt-3** with  $IC_{50}$  of 520 nM.

IC50 & Target: IC50: 880 nM (RET), 170 nM (KDR), 790 nM (Flt-4), 500 nM (c-Kit), 520 nM (Flt-3), 20 nM (Abl)<sup>[1]</sup>

In Vitro: A number of other kinases are also similarly inhibited by AST 487 (NVP-AST487) in the in vitro kinase assays, including KDR (IC $_{50}$ =170 nM), Flt-4 (IC $_{50}$ =790 nM), Flt-3 (IC $_{50}$ =520 nM), c-Kit (IC $_{50}$ =500 nM), and c-Abl (IC $_{50}$ =20 nM). AST 487 potently inhibits the growth of human thyroid cancer cell lines with activating mutations of *RET* but not of lines without *RET* mutations. Both GDNF/GFR $\alpha$ 1 and persephin-induced calcitonin mRNA are markedly inhibited by coincubation with 100 nM of AST 487 in MTC-M cells<sup>[1]</sup>. AST 487 is a novel, mutant FLT3 inhibitor. AST 487 is tested in biochemical assays for inhibition of Flt-3 kinase activity. The K $_{i}$  is determined to be 0.12  $\mu$ M. Besides Flt-3, NVP-AST487 inhibits RET, KDR, c-Kit, and c-Abl kinase with IC $_{50}$  values below 1  $\mu$ M. Treatment of FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells with AST 487 potently inhibits cellular proliferation (IC $_{50}$ [2].

In Vivo: After a single oral administration of 15 mg/kg of AST 487 to OF1 mice, a mean peak plasma level ( $C_{max}$ ) of 0.505±0.078  $\mu$ M SE is achieved after 0.5 h. Similar levels of AST 487 are found in the plasma of mice up to 6 h after oral administration, with a  $C_{last}$  of 21±4 nM at 24 h. The oral bioavailability is calculated to be 9.7% with a  $t_{1/2}$  terminal elimination of 1.5  $h^{[1]}$ .

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!